Todd Brady, Aldeyra Therapeutics CEO

Ab­b­Vie seeks Resta­sis fol­low-up with small op­tion fee for Aldeyra’s eye drops, de­spite a po­ten­tial 'im­mi­nen­t' CRL

As Ab­b­Vie’s sales of its dry eye dis­ease drug Resta­sis con­tin­ue to slide fol­low­ing the first gener­ic ap­proval in Feb­ru­ary 2022 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.